Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Says 'IDO' To Incyte For Imfinzi Marriage

Executive Summary

As the major immuno-oncology players seek out the best combination therapies, AstraZeneca and Incyte are starting a Phase III trial evaluating Imfinzi and the IDO inhibitor epacadostat in Stage III NSCLC.

You may also be interested in...

Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor

The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.

AZ Confident New Cancer Drugs Can Drive Return To Sales Growth

The drugs major is looking to return to sales growth in 2018 and believes that its oncology division will be the main driver as the last wave of patent expiries ebbs away.

Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts